Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Verastem Oncology
< Previous
1
2
Next >
Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer
October 14, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 06, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit
September 28, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology to Participate in Upcoming Investor Conferences
September 05, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers
August 28, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 08, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer
July 11, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
July 05, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants
June 16, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 15, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Reverse Stock Split
May 31, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib
May 25, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors
May 16, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 09, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology to Participate in Upcoming Investor Conferences
May 01, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting
April 26, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days
April 18, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 06, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
New Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer
March 15, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
March 14, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers
February 02, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock
January 24, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
January 24, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 18, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Appoints Rob Gagnon to Board of Directors
December 15, 2022
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 03, 2022
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Appoints Anil Kapur to Board of Directors
October 20, 2022
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 07, 2022
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates
October 04, 2022
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.